baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Argenx SE/ NL0010832176 /

10/11/2024 2:28:58 PM	Chg. -14.85	Volume	Bid10/4/2024	Ask7/25/2024	Market Capitalization	Dividend Y.	P/E Ratio
476.50EUR	-3.02%	23 Turnover: 10,959.50	-Bid Size: -	-Ask Size: -	28.77 bill.EUR	-	-

GlobeNewswire 8/28 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 8/26 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...

GlobeNewswire 8/12 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire 7/25 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

GlobeNewswire 7/18 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...

GlobeNewswire 7/16 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...

GlobeNewswire 7/8 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

GlobeNewswire 6/25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...

GlobeNewswire 6/21 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...

GlobeNewswire 6/17 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...

GlobeNewswire 6/13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

GlobeNewswire 6/4 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 5/9 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/7 argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire 5/7 argenx to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire 5/2 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 4/16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 3/27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 3/26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 3/26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 3/7 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 2/29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 2/26 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2/22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 2/20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

Argenx SE/ NL0010832176 /

If you wish to receive reply to your feedback, please provide your email address.